Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 311

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery

Open access
Mehta, Rajendra H., Leimberger, Jeffrey D., van Diepen, Sean, Meza, James, Wang, Alice, Jankowich, Rachael, Harrison, Robert W., Hay, Douglas, Fremes, Stephen, Duncan, Andra, Soltesz, Edward G., Luber, John, Park, Soon, Argenziano, Michael, Murphy, Edward, Marcel, Randy, Kalavrouziotis, Dimitri, Nagpal, Dave, Bozinovski, John, Toller, Wolfgang, Heringlake, Matthias, Goodman, Shaun G., Levy, Jerrold H., Harrington, Robert A., Anstrom, Kevin J., Alexander, John H. · 2017 · New England Journal of Medicine

Abstract

BACKGROUND: Levosimendan is an inotropic agent that has been shown in small studies to prevent or treat the low cardiac output syndrome after cardiac surgery. METHODS: In a multicenter, randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of levosimendan in patients with a left ventricular ejection fraction of 35% or less who were undergoing cardiac surgery with the use of cardiopulmonary bypass. Patients were randomly assigned to receive either intravenous levosimendan (at a dose of 0.2 μg per kilogram of body weight per minute for 1 hour, followed by a dose of 0.1 μg per kilogram per minute for 23 hours) or placebo, with the infusion started before surgery. The two primary end points were a four-component composite of death through day 30, renal-replacement therapy through day 30, perioperative myocardial infarction through day 5, or use of a mechanical cardiac assist device through day 5; and a two-component composite of death through day 30 or use of a mechanical cardiac assist device through day 5. RESULTS: A total of 882 patients underwent randomization, 849 of whom received levosimendan or placebo and were included in the modified intention-to-treat population. The four-component primary end point occurred in 105 of 428 patients (24.5%) assigned to receive levosimendan and in 103 of 421 (24.5%) assigned to receive placebo (adjusted odds ratio, 1.00; 99% confidence interval [CI], 0.66 to 1.54; P=0.98). The two-component primary end point occurred in 56 patients (13.1%) assigned to receive levosimendan and in 48 (11.4%) assigned to receive placebo (adjusted odds ratio, 1.18; 96% CI, 0.76 to 1.82; P=0.45). The rate of adverse events did not differ significantly between the two groups. CONCLUSIONS: Prophylactic levosimendan did not result in a rate of the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device that was lower than the rate with placebo among patients with a reduced left ventricular ejection fraction who were undergoing cardiac surgery with the use of cardiopulmonary bypass. (Funded by Tenax Therapeutics; LEVO-CTS ClinicalTrials.gov number, NCT02025621 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1616218

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 311

Metadata

Authors
Mehta, R. H., Leimberger, J. D., van Diepen, S., Meza, J., Wang, A., Jankowich, R., Harrison, R. W., Hay, D., Fremes, S., Duncan, A., Soltesz, E. G., Luber, J., Park, S., Argenziano, M., Murphy, E., Marcel, R., Kalavrouziotis, D., Nagpal, D., Bozinovski, J., Toller, W., Heringlake, M., Goodman, S. G., Levy, J. H., Harrington, R. A., Anstrom, K. J., & Alexander, J. H.
Venue
New England Journal of Medicine
Published
2017-05-25
Volume
376
Issue
21
Pages
2032-2042
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2596970432
Cited by
311
References
14
FWCI
39.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. https://app.cochat.ai/papers/10.1056/nejmoa1616218
The paper
Mehta, R. H., Leimberger, J. D., van Diepen, S., Meza, J., Wang, A., Jankowich, R., Harrison, R. W., Hay, D., Fremes, S., Duncan, A., Soltesz, E. G., Luber, J., Park, S., Argenziano, M., Murphy, E., Marcel, R., Kalavrouziotis, D., Nagpal, D., Bozinovski, J., . . . Alexander, J. H. (2017). Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1616218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.